Literature DB >> 32486840

Impact of a Personalized Audit and Feedback Intervention on Antibiotic Prescribing Practices for Outpatient Pediatric Community-Acquired Pneumonia.

Maria Carmen G Diaz1, Lori K Handy2, James H Crutchfield3, Adriana Cadilla4, Jobayer Hossain1, Lloyd N Werk4.   

Abstract

Antibiotic choice for pediatric community-acquired pneumonia (CAP) varies widely. We aimed to determine the impact of a 6-month personalized audit and feedback program on primary care providers' antibiotic prescribing practices for CAP. Participants in the intervention group received monthly personalized feedback. We then analyzed enrolled providers' CAP antibiotic prescribing practices. Participants diagnosed 316 distinct cases of CAP (214 control, 102 intervention); among these 316 participants, 301 received antibiotics (207 control, 94 intervention). In patients ≥5 years, the intervention group had fewer non-guideline-concordant antibiotics prescribed (22/103 [21.4%] control; 3/51 [5.9%] intervention, P < .05) and received more of the guideline-concordant antibiotics (amoxicillin and azithromycin). Personalized, scheduled audit and feedback in the outpatient setting was feasible and had a positive impact on clinician's selection of guideline-recommended antibiotics. Audit and feedback should be combined with other antimicrobial stewardship interventions to improve guideline adherence in the management of outpatient CAP.

Entities:  

Keywords:  audit and feedback; community-acquired pneumonia; pediatric

Mesh:

Substances:

Year:  2020        PMID: 32486840     DOI: 10.1177/0009922820928054

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  1 in total

1.  Cough medicine prescriptions for children were significantly reduced by a systematic intervention that reinforced national recommendations.

Authors:  Sauli Palmu; Paula Heikkilä; Juho E Kivistö; Roope Poutanen; Matti Korppi; Marjo Renko; Péter Csonka
Journal:  Acta Paediatr       Date:  2022-02-17       Impact factor: 4.056

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.